Abstract
The regulation of cellular reduction/oxidation (redox) balance is critically determined by several antioxidant systems such as the thioredoxin-1 (Trx-1) which reduces disulfides on targeted proteins. In addition, intracellular Trx-1 exerts most of its antioxidant properties through scavenging of reactive oxygen species. Moreover, it acts as a cofactor for several enzymes and plays an important role in the regulation of redox-sensitive transcription factors. Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Trx-1 secretion has been reported to occur in conditions associated with oxidative stress and inflammation. Beneficial effects of elevated plasma Trx-1 levels on various pathologies were reported in mice. In conclusion, oxidative stress is an important actor in various pathologies including cardio- and cerebro-vascular diseases. Therefore, controlling the redox status by increasing the activity of Trx-1 seems to be a novel and an attractive approach.
Keywords: Thioredoxin, oxidative stress, antioxidant, inflammation, cardiovascular diseases
Cardiovascular & Hematological Disorders-Drug Targets
Title: Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders
Volume: 8 Issue: 4
Author(s): Ludivine Billiet and Mustapha Rouis
Affiliation:
Keywords: Thioredoxin, oxidative stress, antioxidant, inflammation, cardiovascular diseases
Abstract: The regulation of cellular reduction/oxidation (redox) balance is critically determined by several antioxidant systems such as the thioredoxin-1 (Trx-1) which reduces disulfides on targeted proteins. In addition, intracellular Trx-1 exerts most of its antioxidant properties through scavenging of reactive oxygen species. Moreover, it acts as a cofactor for several enzymes and plays an important role in the regulation of redox-sensitive transcription factors. Several studies have reported that Trx-1 activity can be modulated by the interaction with vitamin D3-upregulated protein (VDUP-1) (also called Txnip for thioredoxin interacting protein-1 or TBP-2 for Trx-binding protein-2). Trx-1 secretion has been reported to occur in conditions associated with oxidative stress and inflammation. Beneficial effects of elevated plasma Trx-1 levels on various pathologies were reported in mice. In conclusion, oxidative stress is an important actor in various pathologies including cardio- and cerebro-vascular diseases. Therefore, controlling the redox status by increasing the activity of Trx-1 seems to be a novel and an attractive approach.
Export Options
About this article
Cite this article as:
Billiet Ludivine and Rouis Mustapha, Thioredoxin-1 is a Novel and Attractive Therapeutic Approach for Various Diseases Including Cardiovascular Disorders, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152908786786179
DOI https://dx.doi.org/10.2174/187152908786786179 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity and Oxidative Stress: Potential Roles of Melatonin as Antioxidant and Metabolic Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Meet the Editorial Board Member
Current Drug Targets Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Endovascular Repair of Thoracic Aortic Aneurysms
Recent Patents on Cardiovascular Drug Discovery Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application
Current Vascular Pharmacology Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Is Hypertension an Inflammatory Process?
Current Pharmaceutical Design Effects of Maternal Obesity On Placental Phenotype
Current Vascular Pharmacology Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Statins and Solid Organ Transplantation
Current Pharmaceutical Design Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Current Vascular Pharmacology Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Patent Selections
Recent Patents on Cardiovascular Drug Discovery Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry